Marshall Wace’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-38,221
| Closed | -$1.15K | – | 3095 |
|
|
2024
Q2 | $1.15K | Buy |
+38,221
| New | +$567K | ﹤0.01% | 2482 |
|
|
2023
Q3 | – | Sell |
-87,037
| Closed | -$1.07M | – | 2894 |
|
|
2023
Q2 | $1.07M | Sell |
87,037
-11,218
| -11% | -$140K | ﹤0.01% | 1688 |
|
|
2023
Q1 | $1.21M | Buy |
+98,255
| New | +$1.15M | ﹤0.01% | 1723 |
|
|
2021
Q3 | – | Sell |
-39,150
| Closed | -$250K | – | 3682 |
|
|
2021
Q2 | $250K | Sell |
39,150
-52,616
| -57% | -$347K | ﹤0.01% | 2383 |
|
|
2021
Q1 | $576K | Buy |
91,766
+35,918
| +64% | +$257K | ﹤0.01% | 1889 |
|
|
2020
Q4 | $385K | Buy |
+55,848
| New | +$275K | ﹤0.01% | 1588 |
|
|
2016
Q4 | – | Sell |
-35,288
| Closed | -$1.76M | – | 1227 |
|
|
2016
Q3 | $1.76M | Buy |
+35,288
| New | +$1.46M | 0.01% | 623 |
|
|
2015
Q4 | – | Sell |
-41,862
| Closed | -$2.8M | – | 1220 |
|
|
2015
Q3 | $2.8M | Sell |
41,862
-20,967
| -33% | -$1.71M | 0.03% | 386 |
|
|
2015
Q2 | $6.11M | Buy |
+62,829
| New | +$5.98M | 0.08% | 268 |
|
|
2014
Q4 | – | Sell |
-22,452
| Closed | -$1.55M | – | 1078 |
|
|
2014
Q3 | $1.55M | Buy |
22,452
+12,591
| +128% | +$673K | 0.02% | 488 |
|
|
2014
Q2 | $566K | Buy |
+9,861
| New | +$501K | 0.01% | 585 |
|
Marshall Wace's MACK Position: Q3 2024 in Review
Marshall Wace sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2024, closing a stake of 38,221 shares — an estimated $1.15K sold.
Marshall Wace first reported a position in MACK in Q2 2014 and held it in 11 quarters. The position peaked at $6.11M in Q2 2015. 2 funds tracked by Wall St. Rank hold MACK as of Q3 2024.
- Marshall Wace reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Marshall Wace sold 38,221 Merrimack Pharmaceuticals, Inc. shares in Q3 2024, an estimated $1.15K.
- Marshall Wace first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 11 quarters.
- Marshall Wace's Merrimack Pharmaceuticals, Inc. position peaked at $6.11M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2024.
Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.